NCT00284089View on ClinicalTrials.gov

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

January 31, 2009

Conditions

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Interventions

DRUG

Ranibizumab

Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.

Trial Locations (1)

Unknown

Novartis, Tokyo